Skip to main content
Premium Trial:

Request an Annual Quote

ABI, Va. Tech, Waters, YMC, Invitrogen, SciQuest, NIH, PerkinElmer, Matritech

Premium
ABI Mass Spec Revs Climb 14 Percent for Q2; Overall Revs Up 10 Percent 
 
Mass spectrometry revenues rose 14 percent during its fiscal second quarter helping drive up overall revenues at Applied Biosystems by 10 percent, the company said this week.
 
For the period ended Dec. 31, revenues generated from mass spec sales totaled $135.9 million, or 26 percent of ABI’s total revenues of $530 million.
 
During ABI’s second quarter of 2006, mass spec sales generated revenues of $119.4 million. The company recorded total revenues of $481.9 million for the year-ago period.
 
Revenues for the quarter ended Dec. 31, 2006 included a favorable impact of slightly more than 3 percent related to the acquisition of Ambion in March 2006, ABI said.
 
For the quarter, ABI said net income rose 142 percent to $74.8 million from $30.9 million a year ago. Income for the year-ago period, however, included a pre-tax charge, severance expense, and amortization expense that in total held down income by $3.7 million, the company said. Figures from a year-ago also included a tax charge of $28 million.
 
The company spent $50.9 million R&D for the quarter. Through six months of its fiscal year, ABI had $343.7 million in cash and short term investments. 
 
Last week, ABI declared a regular quarterly dividend of $.0425 per share of its common stock. The dividend is payable on April 2 o shareholders of record on close of business on March 1.
 

 
Va. Tech Opens MS Center for Proteomics, Metabolomics Research
 
The Institute for Biomedical and Public Health Sciences at Virginia Tech announced this week the creation of its Mass Spectrometry Research Incubator to support proteomics and metabolomics research.
 
The incubator currently has two mass spectrometers, a MALDI/TOF/TOF and a quadrupole-quadrupole-ion trap coupled with a nanoflow LC system. Richard Helm, associate professor of biochemistry, will oversee the incubator.
 
In a statement, Helm said the incubator will be an open facility where students and researchers can discuss research problems and ideas with incubator staff that can help in addressing their concerns or guide their research.
 
“Eventually this will lead to new grants and contracts where investigators collaborate directly with the incubator,” Helm said. “We expect that the research incubator will help individual investigators quickly gain the insight necessary to design and interpret mass spectrometry-based experiments.”
 

 
Waters, YMC Expand HPLC Column Distribution Agreement
 
Waters this week said it will distribute the YMC HPLC analytical and preparative column lines worldwide. Waters already had exclusive distribution rights to the YMC column product line in North, South and Central America, and the Caribbean.
 
Terms of the new agreement were not disclosed.
 
Waters is offering scientists YMC HPLC columns applications notebooks, available in electronic or paper form. The notebook is an application database with more than 400 applications to help chromatographers research columns and develop analytical methods.
 

 
Invitrogen, SciQuest Partnership Eases Electronic Purchase of Invitrogen Products
 
Invitrogen and SciQuest announced this week a partnership to provide an electronic procurement software platform to Invitrogen's customers.
 
SciQuest, based in Research Triangle Park, NC, specializes in on-demand supply management and automated procurement solutions.
 
The partnership will allow customers to use SciQuest's software to electronically purchase products from Invitrogen along with other vendors with a single purchase order, the companies said.
 
Michael Stapleton, Invitrogen’s vice president of e-business and marketing, said the partnership helps create a central portal for customers who “are under pressure to streamline their purchasing processes.”
 
The companies also said they have signed "numerous" customers for the new offering, including the Wellcome Trust Sanger Institute, Exelixis, and Apoxis.
 

 
NIH Holding Workshops to Review NIH Grant Application Process
 
The National Institutes of Health’s Center for Scientific Review will hold six one-day open house workshops to solicit input from the scientific community beginning in March.
 
The workshops are “critical to realigning and reinventing CSR’s application review groups so the $20 billion-plus NIH invests in biomedical research grants each year advances the most promising research,” the NIH said in a statement. CSR’s peer review groups have not been assessed broadly by the scientific community since the NIH Panel on Scientific Boundaries for Review released its reorganization plans seven years ago.
 
The first workshop, on March 2, will focus on the CSR’s neuroscience study sections. Additional workshops will be held every other month focusing on behavioral and social sciences study sections; disease-based study sections; integrated biological study sections, to be held in two workshops; and biomolecular study sections. 
 
Additional information and registration forms can be found here.
 

 
PerkinElmer Declares Dividend
 
PerkinElmer’s board this week declared a regular quarterly dividend of $.07 per share of common stock payable on May 11 to shareholders of record at the close of business on April 20.
 

 
Matritech Closes on Series B Financing
 
Matritech announced this week it has closed a $4.36 million private place of Series B 15 percent secured convertible promissory notes and warrants to purchase 4.15 million shares of common stock. The promissory notes mature on Dec. 13.
 
Participants in this round included current investors SDS Capital Group SPC and H&Q Life Science Investors. Matritech’s net proceeds after deducted expenses and commissions are about $3.8 million.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.